Prognostic subtyping based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor2 expression in breast cancer cases among north Indian females
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20183578Keywords:
Breast cancer, Receptor status, North IndiaAbstract
Background: Cancer of breast has recently become the leading cancer among women in Kashmir. Worse prognosis of this disease is with the features of higher grade, positivity for Her-2/neu, negativity for ER, PR, and presence of BRCA gene. Thus the receptor status like are a very useful tool for rapid diagnosis, treatment as well as for prognosis of the disease. The objective of the study was to analyze the pattern of expression of hormone receptors which include ER, PR and Her-2/neu in breast cancer cases among Kashmiri females and to find their association with various clinicopathological parameters.
Methods: A cross sectional hospital based study done in a tertiary health care centre of Kashmir valley. We selected 102 consecutive breast cancer cases for the period of one year. Cases were sent for biopsy of the tumour lesion and for receptor status analysis.
Results: In about 50.9%of cases tumour had spread to T2 stage. There was a significant difference in the tumor stage and the age groups at presentation. The HER 2 status was positive in 85.5% of cases. About 65% were ER positive and 51.9 were PR positive. Only 8 were triple negative and 42 were triple positive for receptors. We did not found any significant relationship between grade, stage of disease and age when compared for receptor status.
Conclusions: We found a high percentage being receptor positive tumours which has been found to be a good prognostic sign.
References
Torre L, Rebecca Siegel AJ. Global Cancer Facts & Figures 3rd Edition. American Cancer Society; 2015.
Indian Council of Medical Research. Consensus Document for Management of Breast Cancer. 2014: 1–40.
Wani MA, Jan FA, Khan NA, Pandita KK, Khurshid R, Khan SH. Cancer trends in Kashmir; common types, site incidence and demographic profiles: National Cancer Registry 2000-2012. Indian J Cancer. 2014;51(2):133–7.
Laamiri FZ, Bouayad A, Hasswane N, Ahid S. Risk Factors for Breast Cancer of Different Age Groups : Moroccan Data ? J Obstet Gynecol. 2015;5:79–87.
Hormone Therapy for Breast Cancer. American Cancer Society. 2016. Available at: https://www. cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html. Accesssed on 24 February 2018.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13.
Biswal P, Behera S, Kar A, Pradhan D. Correlation of Hormonal Receptors Estrogen Receptor, Progesterone Receptor and Her-2 / Neu with Tumor Characteristics in Breast Carcinoma : Study of 100 Consecutive Cases. Int J Clin Med. 2015;12:961–6.
Rajan G, Culas TB, Jayalakshmy P. Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India. World J Surg Oncol. 2014;12(1):120.
Kinsella MD, Nassar A, Siddiqui MT, Cohen C. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience. Int J Clin Exp Pathol. 2012;5(6):530–6.
Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer. Medicine (Baltimore). 2016;95(35):e4614.
Ma KK, Chau WW, Wong CHN, Wong K, Fung N, Lee JTA, et al. Triple Negative Status is a Poor Prognostic Indicator in Chinese Women with Breast Cancer: a Ten Year Review. Asian Pacific J Cancer Prev. 2012;13(5):2109–14.
